An observational study in Cardiovascular Disease and Menopause, sponsored by Alexandra Hospital. Active, not recruiting at 1 site in Singapore. Open to female participants aged 45 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-08-01.
Sponsored by Alexandra Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study examines the factors that limit or support the implementation of a pilot heart health program for perimenopausal women. The investigators evaluate the effectiveness of this program in raising awareness and promoting behavior change to maintain cardiovascular health.
Cardiovascular disease (CVD) is the leading cause of mortality among women. Heart-related conditions are responsible for the death of one out of every three women. In Singapore, CVD in women causes more morbidity and mortality than breast and cervical cancer. The burden will be exacerbated by Singapore's aging population and the longer life expectancy of women compared to men. Primary and secondary prevention strategies are implemented to reduce the overall impact of CVD on public health. Women who have traditional risk factors are at a greater risk of experiencing heart attacks compared to men with comparable risk factors. Additional risks specific to women include a history of pregnancy complications, breast cancer, and premature menopause. CVDs in women are frequently overlooked in terms of diagnosis and treatment.
Menopause is a phase in a woman's life that brings about significant changes to both her reproductive organs and her physical and psychological well-being. Management issues encompass a spectrum of concerns, including immediate symptoms like insomnia and palpitations, intermediate concerns related to bone health, and long-term considerations associated with the development of cardiovascular disease. The American Heart Association (AHA) provides guidelines for multidisciplinary care aimed at preventing cardiovascular disease (CVD) in women. Countries like Canada have established specialized organizations to address this issue. Collaborative clinics involving cardiologists, gynecologists, and women's heart centers are crucial, even for women who are generally healthy.
The objective of this study is to examine the factors that limit or support the implementation of a preventive heart health program for perimenopausal women. Additionally, the investigators aim to evaluate the effectiveness of our pilot women's health program in raising awareness and promoting behavior change to maintain cardiovascular health.
5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.
This study's planned enrollment of 120 is below the median of 534 across 1,577 observational studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →Alexandra Hospital is the lead sponsor of 8 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Women going through the menopause transition with risk factors for CVD or pre-existing CVD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Women aged 45-65 years with risk factors or pre-existing CVD
Other: Preventive heart health and menopause programme
This is a one-stop women's heart and menopausal service in a public hospital led by cardiologists and gynaecologists with a multidisciplinary team. Pre-existing speciality care and services are repackaged, and clinic workflows are reworked to provide more streamlined, convenient, and integrated care. Services encompass: * Individualised risk assessment, screening, diagnosis, and treatment of CVD. * Lifestyle education, adjustment, stress management, and counselling. * Smoking cessation programs. * Bone health screening, mammogram with access to our co-located gynaecologists and hormone replacement therapy. * Virtual consults and health coaching.
Reach of the programme
This a part of the RE-AIM comprehensive method for programme evaluation. This is measured via participation rate which is the number of eligible women recruited (numerator) divided by the number of eligible women screened for the programme (denominator
Time frame: 1 year
Effectiveness of the programme
This a part of the RE-AIM comprehensive method for programme evaluation. This is measured via the GPAQ (Global physical activity questionnaire)
Time frame: 1 year
Effectiveness of the programme
This a part of the RE-AIM comprehensive method for programme evaluation. This is measured via the Utian Quality of life scale.
Time frame: 1 year
Adoption of the programme
This a part of the RE-AIM comprehensive method for programme evaluation. This is measured via qualitative interviews to assess whether healthcare providers are accepting of the intervention and can sustain the change.
Time frame: 1 year
Implementation of the programme
This will be measured as counts from clinic visits
Time frame: 1 year
Anthropometric measurements
Weight and height will be combined to report BMI in kg/m\^2
Time frame: 1 year
Blood pressure
Office blood pressure measurements
Time frame: 1 year
Blood biomarkers
Hba1c
Time frame: 1 year
Blood biomarkers
Lipid profile
Time frame: 1 year
Blood biomarkers
Vitamin D levels
Time frame: 1 year
Surveys
Semi structure interviews will be conducted and analysed via reflexive thematic approach.
Time frame: At the end of the study at 1 year
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2023 (actual). Primary completion is estimated for Sep 2024, 15 months after the start.
Of 583 non-industry observational studies under Cardiovascular Diseases, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 196. This study's planned 15 months is below that.
Counting every sponsor, half of 667 studies reached it within 62 months; a quarter within 24 and three quarters within 192.
Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Alexandra Hospital